



Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause 41 of the Listing Agreement, for the quarter and year ended on 31st March, 2013

Rs. lakhs

	THREE MONTHS ENDED			YEAR ENDED	
	31-MAR-2013	31-DEC-2012	31-MAR-2012	31-MAR-2013	31-MAR-2012
01. Segment Revenue (Net)					
a) Bulk Chemicals	6562	6743	3421	23692	15662
b) Formulations	7572	6982	8485	29367	27126
c) Job Work	219	255	205	944	896
d) Unallocated	254	1391	682	3244	1416
Total	14607	15371	12793	57247	45100
Less : Inter-segment Revenue	276	340	221	1322	1521
Net Sales / Income from Operations	14331	15031	12572	55925	43579
02. Segment Results : Profit (+)/Loss (-) before tax and interest					
a) Bulk Chemicals	1541	1614	741	5527	2943
b) Formulations	3136	2531	1805	12235	9688
c) Job Work	129	208	169	728	727
d) Unallocated	223	1253	607	2915	1235
Total	5029	5606	3322	21405	14593
Less : a) Interest	770	731	609	2512	2296
b) Other unallocable expenditure	2162	1958	728	8855	4986
c) Unallocable income	(203)	(570)	-74	(1194)	(940)
Total Profit Before Tax	2300	3487	2059	11232	8251
03. Capital Employed (Segment Assets - Segment Liabilities)					
a) Bulk Chemicals	36375	37939	32093	36375	32093
b) Formulations	32742	31251	28721	32742	28721
c) Job Work	94	48	178	94	178
e) Unallocated (Others)	-15453	-16688	-14246	-15453	-14246
Total	53758	52550	46746	53758	46746

The above financial results were reviewed / audited by the Statutory Auditors of the Company, the Audit Committee, and approved by the Board of Directors at a meeting held at Hyderabad, on Thursday, the 30th May, 2013. In respect of reference relating to non-accounting of minimum alternate tax credit, in the auditors' report, the company will review and evaluate the position during the current financial year. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Figures for the quarter ended on 31st March are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the financial year. Exceptional item represents amount written off against a pending legal dispute. The stand-alone results are available on the company's web-site www.natcopharma.co.in.

Dated at Hyderabad, this, the 30th day of May, 2013.

for and on behalf of the Board of Directors,

NATCO Pharma Limited

V.C. Nannapaneni

Chairman & Managing Director

Regd. Office: **NATCO** House, Road # 2, Banjara Hills, **Hyderabad : 500 033.**




Statement of consolidated Financial Results for the quarter and year ended 31st March, 2013

Rs. lakhs

PARTICULARS	THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)			YEAR ENDED	
	31-MAR-2013	31-DEC-2012	31-MAR-2012	31-MAR-2013 (UN-AUDITED)	31-MAR-2012 (AUDITED)
01. Gross Sales / Income from Operations	16156	16515	14166	65302	52953
Less : Excise Duty	430	508	179	2122	1347
Less : Sales Tax	278	229	313	1101	1119
Net Sales / Income from Operations	15448	15778	13674	62079	50487
02. Other Operating Income	1351	1983	1218	4390	2605
03. TOTAL INCOME FROM OPERATIONS	16799	17761	14892	66469	53092
04. EXPENDITURE					
a) Cost of materials consumed	6220	7153	5372	25824	18660
b) Purchases of stock-in-trade	226	55	330	714	1553
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-755	-527	-42	-2191	75
d) Employee benefits expense	2543	2447	2176	10233	7777
e) Depreciation and amortization expense	625	634	166	2212	1583
f) Other Expenses	5143	4109	4473	16900	13478
TOTAL EXPENSES	14002	13871	12475	53692	43126
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	2797	3890	2417	12777	9966
06. Other Income	184	593	74	1239	350
07. Finance costs	823	758	621	2631	2362
08. Exceptional Item	-	541	-	1158	-
09. Profit / (Loss) from ordinary activities before tax	2158	3184	1870	10227	7954
10. Tax expense, including deferred tax	1178	1061	619	3501	2107
11. Minority Interest	-223	-136	-14	-531	-114
12. Net Profit / Loss (-) from ordinary activities after tax	1203	2259	1265	7257	5961
13. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3137	3115	3137	3115
14. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				50287	44086
15. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	3.83 3.83	7.20 7.20	4.35 4.35	23.23 23.13	20.53 20.53
16. Public Shareholding:					
a) Number of Shares	13,594,593	13,603,193	13,378,081	13,594,593	13,378,081
b) Percentage of Shareholding	43.33	43.36	42.95	43.33	42.95
16. Promoters and Promoter Group Shareholding					
a) Pledged / Encumbered – No. of shares	-	-	-	-	-
b) Non – encumbered – No. of shares	17,778,481	17,769,881	17,769,881	17,778,481	17,769,881
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	56.67	56.64	57.05	56.67	57.05

The stand-alone results are available on the company's web-site www.natcopharma.co.in.

Dated at Hyderabad, this, the 30th May, 2013.
for and on behalf of the Board of Directors,
NATCO Pharma Limited


V.C. Nannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 31st March, 2013

Pending as on 01-01-2013	Nil
Received during the quarter	57
Resolved during the quarter	57
Pending as on 31-03-2013	Nil

Regd. Office: **NATCO** House, Road # 2, Banjara Hills, **Hyderabad : 500 033.**



Statement of Consolidated Assets and Liabilities (Rs. in lakhs)

Particulars	As at 31-Mar-2013	As at 31-Mar-2012
Equity & Liabilities		
Shareholders' Funds		
a) Share Capital	3137	3115
b) Reserves & Surplus	50287	44249
Sub-total : Shareholders' funds	53424	47364
c) Minority Interest	1121	88
Non-current liabilities		
a) Long term borrowings	13783	13410
b) Deferred tax liabilities (net)	4290	2930
c) Other long-term liabilities	69	135
d) Long term provisions	866	659
Sub-total : Non-current Liabilities	19008	17134
Current Liabilities		
a) Short term borrowings	14774	8164
b) Trade payables	11388	9236
c) Other current liabilities	8193	8191
d) Short-term provisions	132	344
Sub-total : Current Liabilities	34487	25935
TOTAL – EQUITY AND LIABILITIES	108040	90521
Assets		
Non-current Assets		
a) Fixed Assets		
- Tangible Assets	55390	30091
- Intangible Assets	2884	1865
b) Capital work-in-progress	10583	16443
c) Non-current investments	154	6179
d) Long term loans and advances	5551	6622
e) Other non-current assets	14	42
Sub-total : Non-current Assets	74576	61242
Current Assets		
a) Current Investments	81	74
b) Inventories	14603	11039
c) Trade receivables	12971	9469
d) Cash and cash equivalents	1265	3663
e) Short term loans and advances	4208	4650
f) Other current assets	336	384
Sub-total : Current Assets	33464	29279
TOTAL – ASSETS	108040	90521




Statement of stand-alone Financial Results for the quarter and year ended 31st March, 2013

Rs. lakhs

PARTICULARS	THREE MONTHS ENDED (UN-AUDITED)			YEAR ENDED (AUDITED)	
	31-MAR-2013	31-DEC-2012	31-MAR-2012	31-MAR-2013	31-MAR-2012
PART I : STATEMENT OF STAND-ALONE RESULTS					
01. Gross Sales / Income from Operations	13536	13788	11839	54656	44150
Less : Excise Duty	435	508	179	2122	1347
Less : Sales Tax	278	229	313	1101	1119
Net Sales / Income from Operations	12823	13051	11347	51433	41684
02. Other Operating Income	1508	1980	1225	4492	1895
03. TOTAL INCOME FROM OPERATIONS	14331	15031	12572	55925	43579
04. EXPENDITURE					
a) Cost of materials consumed	4774	5064	3413	18063	11768
b) Purchases of stock-in-trade	70	55	330	558	1553
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-690	-527	-42	-2125	75
d) Employee benefits expense	2087	1878	1814	8536	6713
e) Depreciation and amortization expense	536	550	378	1984	1541
f) Other Expenses	4688	3822	4085	15201	12322
TOTAL EXPENSES	11465	10842	9978	42217	33972
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	2866	4189	2594	13708	9607
06. Other Income	203	570	74	1194	940
07. Finance costs	769	731	609	2512	2296
08. Exceptional Items	-	541	-	1158	-
09. Profit / (Loss) from ordinary activities before tax	2300	3487	2059	11232	8251
10. Tax expense, including deferred tax	1128	1050	606	3419	2038
11. Net Profit / Loss (-) from ordinary activities after tax	1172	2437	1453	7813	6213
12. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3137	3115	3137	3115
13. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				50621	43632
14. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	3.74 3.74	7.79 7.79	5.00 5.00	25.02 24.91	21.39 21.39
15. Public Shareholding:					
a) Number of Shares	13,594,593	13,603,193	13,378,081	13,594,593	13,378,081
b) Percentage of Shareholding	43.33	43.36	42.95	43.33	42.95
16. Promoters and Promoter Group Shareholding					
a) Pledged / Encumbered –	-	-	-	-	-
b) Non – encumbered – No. of shares	17,778,481	17,769,881	17,769,881	17,778,481	17,769,881
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	56.67	56.64	57.05	56.67	57.05

Dated at Hyderabad, this, the 30th day of May, 2013.
for and on behalf of the Board of Directors,
NATCO Pharma Limited


V.C. Nannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 31st March, 2013

Pending as on 01-01-2013	Nil
Received during the quarter	57
Resolved during the quarter	57
Pending as on 31-03-2013	Nil



Statement of stand-alone Assets and Liabilities (Rs. in lakhs)

Particulars	As at 31-Mar-2013	As at 31-Mar-2012
Equity & Liabilities		
Shareholders' Funds		
a) Share Capital	3137	3115
b) Reserves & Surplus	50621	43632
Sub-total : Shareholders' funds	53758	46747
Non-current liabilities		
a) Long term borrowings	13713	13410
b) Deferred tax liabilities (net)	4112	2889
c) Other long-term liabilities	69	135
d) Long term provisions	821	659
Sub-total : Non-current Liabilities	18715	17093
Current Liabilities		
a) Short term borrowings	14774	8164
b) Trade payables	10443	8387
c) Other current liabilities	8025	8184
d) Short-term provisions	33	342
Sub-total : Current Liabilities	33275	25077
TOTAL – EQUITY AND LIABILITIES	105748	88917
Assets		
Non-current Assets		
a) Fixed Assets		
- Tangible Assets	46565	30003
- Intangible Assets	491	178
b) Capital work-in-progress	7837	16443
c) Non-current investments	7753	7416
d) Long term loans and advances	12066	7578
e) Other non-current assets	13	42
Sub-total : Non-current Assets	74725	61660
Current Assets		
a) Current Investments	81	74
b) Inventories	12832	9728
c) Trade receivables	12646	9334
d) Cash and cash equivalents	937	3370
e) Short term loans and advances	4192	4264
f) Other current assets	335	487
Sub-total : Current Assets	31023	27257
TOTAL – ASSETS	105748	88917



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

Hyderabad, 30th May, 2013

NATCO posts higher revenues, profits !!!

The Board of **NATCO** Pharma met at Hyderabad today to adopt the stand-alone audited accounts of the company for the year ended 31st March, 2013.

The Company had posted a 14% increase in its net revenues at Rs. 143 Crores for the quarter ended 31st March, 2013, as against Rs. 126 Crores for the same quarter last year. The net profit after tax for the quarter ended 31st March, 2013 was 11.72 Crores (as against Rs. 14.53 Crores last year). The profit would have been higher, but for an additional non-cash deferred tax liability of Rs. 7 Crores during the quarter, due to increased capital expenditure.

The Company had, however, posted a 28% increase in its net revenues at Rs. 559 Crores for the year ended 31st March, 2013 – as against Rs. 435 Crores during the last year. The Company had earned a profit after tax of Rs. 78 Crores against Rs. 62 Crores last year.

The strong performance was driven by a 51% growth in the revenues from the active pharmaceutical ingredients segment (Rs. 223 Crores as against Rs. 148 Crores last year), and a 58% increase in revenues from the finished dosage pharmaceutical formulation exports (Rs. 103 Crores as against Rs. 65 Crores last year). The company expects to grow at 15% - 20% this financial year.

Forwarded for favor of publication

For NATCO Pharma Limited

A handwritten signature in black ink, appearing to read "M Adinarayana".

**M Adinarayana
Company Secretary &
G.M. (Legal & Corp Affairs)**